To inform clinicians on the best biologic agent for different populations of adults with severe asthma, 12 experts ...
Whereas natural tolerance rates are generally high for common allergens, such as eggs, milk, and wheat, allergies to other foods often persist beyond childhood. For instance, approximately 72.2% of ...
The FDA's approval of the new dosing option for Omlyclo addresses the diverse needs of patients with allergic and inflammatory conditions. "The approval of the additional 300 mg presentation of Omlyco ...
Xolair is a brand-name prescription medication and is a biologic. Its active ingredient is called omalizumab. Generic versions of biologic medications are called biosimilars. Due to complex ...
Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 ...
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...
Her health insurance company, Blue Cross Blue Shield of Illinois, will begin requiring prior authorization for in-office treatments, according to a release. Blue Cross Blue Shield offices in Texas, ...
The change will make asthma infusion treatments a pharmacy benefit, meaning policyholders will have to self-inject these four asthma infusion medications. Mykal McEldowney/IndyStar USA TODAY NETWORK A ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results